Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Sports Med ; 35(12): 2126-30, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17702995

ABSTRACT

BACKGROUND: Athletes with repetitive weightbearing hyperextension activities are predisposed to wrist pain. PURPOSE: To describe extensor retinaculum impingement of the extensor tendons as a new diagnosis for wrist pain for the athlete performing repetitive wrist hyperextension, to present cadaveric dissections to further understand the anatomical basis for extensor retinaculum impingement, and to report treatment outcomes of extensor retinaculum impingement. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: A retrospective chart review was performed for athletes treated from 1987 to 2006 for wrist pain due to extensor retinaculum impingement. Eight wrists in 7 athletes were reviewed with a mean presenting age of 19.6 years. The hallmark symptom was dorsal wrist pain, and signs were extensor tendon synovitis and tenderness at the distal border of the extensor retinaculum, provoked by wrist hyperextension. Ten cadaveric wrists were dissected and examined to evaluate anatomical factors that may contribute to extensor retinaculum impingement. RESULTS: Two athletes (2 wrists) were treated with corticosteroid injections. Five patients (6 wrists) were treated operatively, with pathologic findings of thickening of the distal border of the extensor retinaculum and concomitant extensor tendon synovial thickening or, in 1 patient, tendon rupture. Partial distal resection of the extensor retinaculum was performed to eliminate impingement. All patients had complete relief of pain and full return to sport. CONCLUSION: Competitive sports that require repetitive wrist extension with an axial load predispose the athlete to extensor retinaculum impingement. Athletes with dorsal wrist pain and tenosynovial thickening worsened with wrist hyperextension should be considered for the diagnosis of extensor retinaculum impingement. When nonoperative management fails, surgical resection of the distal impinging border of the extensor retinaculum can eliminate pain and can still allow athletes to return to sport without diminishing the opportunity for significant athletic accomplishments.


Subject(s)
Athletic Injuries/diagnosis , Tendinopathy/diagnosis , Wrist Injuries/diagnosis , Adolescent , Adult , Athletic Injuries/pathology , Athletic Injuries/therapy , Dissection , Female , Humans , Male , Retrospective Studies , Tendinopathy/pathology , Tendinopathy/therapy , Wrist Injuries/pathology , Wrist Injuries/therapy
2.
J Pain Symptom Manage ; 29(5 Suppl): S32-46, 2005 May.
Article in English | MEDLINE | ID: mdl-15907645

ABSTRACT

Pain is the cancer-related event that is most disruptive to the cancer patient's quality of life. Although bone cancer pain is one of the most severe and common of the chronic pains that accompany breast, prostate, and lung cancers, relatively little is known about the mechanisms that generate and maintain this pain. Recently, we developed a mouse model of bone cancer pain. Ten days following tumor implantation into the intramedullary space of the femur, significant bone destruction and bone cancer pain-related behaviors were observed and progressed in severity over time. A critical question is how closely this model mirrors human bone cancer pain. In a recent publication, we show that, as in humans, pain-related behaviors are diminished by systemic morphine administration in a dose-dependent fashion that is naloxone-reversible. Humans suffering from bone cancer pain generally require significantly higher doses of morphine as compared to individuals with inflammatory pain and in the mouse model the doses of morphine required to block bone cancer pain-related behaviors were 10 times that required to block peak inflammatory pain behaviors of comparable magnitude induced by hindpaw injection of complete Freund's adjuvant (CFA; 1-3 mg/kg). As these animals were treated acutely, there was not time for morphine tolerance to develop and the rightward shift in analgesic efficacy observed in bone cancer pain versus inflammatory pain suggests a fundamental difference in the underlying mechanisms that generate bone cancer versus inflammatory pain. These results indicate that this model will be useful in defining drug therapies that are targeted for complex bone cancer pain syndromes.


Subject(s)
Bone Neoplasms/complications , Disease Models, Animal , Pain/etiology , Palliative Care , Animals , Humans
3.
Exp Neurol ; 193(1): 85-100, 2005 May.
Article in English | MEDLINE | ID: mdl-15817267

ABSTRACT

Bone is the most common site of chronic pain in patients with metastatic cancer. What remains unclear are the mechanisms that generate this pain and why bone cancer pain can be so severe and refractory to treatment with opioids. Here we show that following injection and confinement of NCTC 2472 osteolytic tumor cells within the mouse femur, tumor cells sensitize and injure the unmyelinated and myelinated sensory fibers that innervate the marrow and mineralized bone. This tumor-induced injury of sensory nerve fibers is accompanied by an increase in ongoing and movement-evoked pain behaviors, an upregulation of activating transcription factor 3 (ATF3) and galanin by sensory neurons that innervate the tumor-bearing femur, upregulation of glial fibrillary acidic protein (GFAP) and hypertrophy of satellite cells surrounding sensory neuron cell bodies within the ipsilateral dorsal root ganglia (DRG), and macrophage infiltration of the DRG ipsilateral to the tumor-bearing femur. Similar neurochemical changes have been described following peripheral nerve injury and in other non-cancerous neuropathic pain states. Chronic treatment with gabapentin did not influence tumor growth, tumor-induced bone destruction or the tumor-induced neurochemical reorganization that occurs in sensory neurons or the spinal cord, but it did attenuate both ongoing and movement-evoked bone cancer-related pain behaviors. These results suggest that even when the tumor is confined within the bone, a component of bone cancer pain is due to tumor-induced injury to primary afferent nerve fibers that innervate the tumor-bearing bone. Tumor-derived, inflammatory, and neuropathic mechanisms may therefore be simultaneously driving this chronic pain state.


Subject(s)
Bone Neoplasms/pathology , Neurons, Afferent/pathology , Pain/etiology , Pain/pathology , Polyneuropathies/etiology , Polyneuropathies/pathology , Afferent Pathways/chemistry , Afferent Pathways/pathology , Animals , Bone Neoplasms/complications , Male , Mice , Mice, Inbred C3H , Neurons, Afferent/chemistry
4.
Pain ; 111(1-2): 169-80, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15327821

ABSTRACT

Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival.


Subject(s)
Alendronate/pharmacology , Bone Neoplasms/drug therapy , Osteolysis/drug therapy , Pain/drug therapy , Sarcoma/drug therapy , Activating Transcription Factor 3 , Animals , Behavior, Animal , Biomarkers, Tumor , Bone Neoplasms/complications , Bone Neoplasms/pathology , Male , Mice , Mice, Inbred C3H , Necrosis , Osteoclasts/drug effects , Osteoclasts/pathology , Osteolysis/etiology , Osteolysis/pathology , Pain/etiology , Pain/pathology , Sarcoma/complications , Sarcoma/pathology , Transcription Factors/metabolism
5.
Int J Cancer ; 104(5): 550-8, 2003 May 01.
Article in English | MEDLINE | ID: mdl-12594809

ABSTRACT

Pain is the most common presenting symptom in patients with bone cancer and bone cancer pain can be both debilitating and difficult to control fully. To begin to understand the mechanisms involved in the generation and maintenance of bone cancer pain, we implanted 3 well-described murine tumor cell lines, 2472 sarcoma, B16 melanoma and C26 colon adenocarcinoma into the femur of immunocompromised C3H-SCID mice. Although each of the tumor cell lines proliferated and completely filled the intramedullary space of the femur within 3 weeks, the location and extent of bone destruction, the type and severity of the pain behaviors and the neurochemical reorganization of the spinal cord was unique to each tumor cell line injected. These data suggest that bone cancer pain is not caused by a single factor such as increased pressure induced by intramedullary tumor growth, but rather that multiple factors are involved in generating and maintaining bone cancer pain.


Subject(s)
Bone Neoplasms/complications , Bone Neoplasms/pathology , Central Nervous System/pathology , Pain/complications , Pain/pathology , Animals , Bone Neoplasms/classification , Central Nervous System/chemistry , Male , Mice , Mice, SCID , Neoplasm Transplantation , Pain Measurement , Peripheral Nervous System/chemistry , Peripheral Nervous System/pathology , Tumor Cells, Cultured
6.
Cancer Res ; 62(24): 7343-9, 2002 Dec 15.
Article in English | MEDLINE | ID: mdl-12499278

ABSTRACT

More than half of all chronic cancer pain arises from metastases to bone, and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Several tumor types including sarcomas and breast, prostate, and lung carcinomas grow in or preferentially metastasize to the skeleton where they proliferate, and induce significant bone remodeling, bone destruction, and cancer pain. Many of these tumors express the isoenzyme cycloxygenase-2 (COX-2), which is involved in the synthesis of prostaglandins. To begin to define the role COX-2 plays in driving bone cancer pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined to the intramedullary space of the femur in male C3HHeJ mice. After tumor implantation, mice develop ongoing and movement-evoked bone cancer pain-related behaviors, extensive tumor-induced bone resorption, infiltration of the marrow space by tumor cells, and stereotypic neurochemical alterations in the spinal cord reflective of a persistent pain state. Thus, after injection of tumor cells, bone destruction is first evident at day 6, and pain-related behaviors are maximal at day 14. A selective COX-2 inhibitor was administered either acutely [NS398; 100 mg/kg, i.p.] on day 14 or chronically in chow [MF. tricyclic; 0.015%, p.o.] from day 6 to day 14 after tumor implantation. Acute administration of a selective COX-2 inhibitor attenuated both ongoing and movement-evoked bone cancer pain, whereas chronic inhibition of COX-2 significantly reduced ongoing and movement-evoked pain behaviors, and reduced tumor burden, osteoclastogenesis, and bone destruction by >50%. The present results suggest that chronic administration of a COX-2 inhibitor blocks prostaglandin synthesis at multiple sites, and may have significant clinical utility in the management of bone cancer and bone cancer pain.


Subject(s)
Bone Neoplasms/complications , Bone Neoplasms/drug therapy , Cyclooxygenase Inhibitors/pharmacology , Isoenzymes/antagonists & inhibitors , Osteosarcoma/complications , Osteosarcoma/drug therapy , Pain/drug therapy , Animals , Bone Neoplasms/enzymology , Bone Neoplasms/pathology , Cell Division/drug effects , Cyclooxygenase 2 , Cyclooxygenase 2 Inhibitors , Disease Models, Animal , Hyperostosis/drug therapy , Hyperostosis/enzymology , Hyperostosis/pathology , Male , Mice , Mice, Inbred C3H , Neurons, Afferent/drug effects , Neurons, Afferent/physiology , Osteoclasts/cytology , Osteoclasts/drug effects , Osteoclasts/pathology , Osteosarcoma/enzymology , Osteosarcoma/pathology , Pain/enzymology , Pain/etiology , Prostaglandin-Endoperoxide Synthases , Spinal Cord/drug effects , Spinal Cord/physiopathology
7.
Pain ; 99(3): 397-406, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12406514

ABSTRACT

Pain is the cancer related event that is most disruptive to the cancer patient's quality of life. Although bone cancer pain is one of the most severe and common of the chronic pains that accompany breast, prostate and lung cancers, relatively little is known about the mechanisms that generate and maintain this pain. Recently, we developed a mouse model of bone cancer pain and 16 days following tumor implantation into the intramedullary space of the femur, significant bone destruction and bone cancer pain-related behaviors were observed. A critical question is how closely this model mirrors human bone cancer pain. In the present study we show that, as in humans, pain-related behaviors are diminished by systemic morphine administration in a dose dependent fashion that is naloxone-reversible. Humans suffering from bone cancer pain generally require significantly higher doses of morphine as compared to individuals with inflammatory pain and in the mouse model, the doses of morphine required to block bone cancer pain-related behaviors were ten times that required to block peak inflammatory pain behaviors of comparable magnitude induced by hindpaw injection of complete Freund's adjuvant (CFA) (1-3mg/kg). As these animals were treated acutely, there was not time for morphine tolerance to develop and the rightward shift in analgesic efficacy observed in bone cancer pain vs. inflammatory pain suggests a fundamental difference in the underlying mechanisms that generate bone cancer vs. inflammatory pain. These results indicate that this model may be useful in defining drug therapies that are targeted for complex bone cancer pain syndromes.


Subject(s)
Bone Neoplasms/drug therapy , Morphine/therapeutic use , Pain/drug therapy , Animals , Bone Neoplasms/physiopathology , Dose-Response Relationship, Drug , Inflammation/drug therapy , Inflammation/physiopathology , Male , Mice , Mice, Inbred C3H , Pain/physiopathology , Pain Measurement/methods , Sarcoma, Experimental/drug therapy , Sarcoma, Experimental/physiopathology
8.
Pain ; 95(1-2): 175-86, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11790480

ABSTRACT

Although pains arising from the craniofacial complex can be severe and debilitating, relatively little is known about the peripheral and central mechanisms that generate and maintain orofacial pain. To better understand the neurons in the trigeminal complex and spinal cord that are activated following nociceptive stimuli to the orofacial complex, we examined substance P (SP) induced internalization of substance P receptors (SPR) in neurons following dental extraction in the rat. Unilateral gingival reflection or surgical extraction of a rat maxillary incisor or molar was performed and tissues harvested at various time points post-extraction. Immunohistochemical analysis of brainstem and cervical spinal cord sections was performed using an anti-SPR antibody and confocal imaging. Both the number and location of neurons showing SPR internalization was dependent on the location and extent of tissue injury. Whereas extraction of the incisor induced internalization of SPR in neurons bilaterally in nucleus caudalis and the spinal cord, extraction of the molar induced strictly unilateral internalization of SPR-expressing neurons in the same brain structures. Minor tissue injury (retraction of the gingiva) activated SPR neurons located in lamina I whereas more extensive and severe tissue injury (incisor or molar extraction) induced extensive SPR internalization in neurons located in both laminae I and III-V. The rostrocaudal extent of the SPR internalization was also correlated with the extent of tissue injury. Thus, following relatively minor tissue injury (gingival reflection) neurons showing SPR internalization were confined to the nucleus caudalis while procedures which cause greater tissue injury (incisor or molar extraction), neurons showing SPR internalization extended from the interpolaris/caudalis transition zone through the C7 spinal level. Defining the population of neurons activated in orofacial pain and whether analgesics modify the activation of these neurons should provide insight into the mechanisms that generate and maintain acute and chronic orofacial pain.


Subject(s)
Neurons/chemistry , Pain/metabolism , Receptors, Neurokinin-1/metabolism , Spinal Cord/chemistry , Tooth Extraction , Trigeminal Nucleus, Spinal/chemistry , Animals , Male , Neurons/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Neurokinin-1/analysis , Spinal Cord/metabolism , Substance P/analysis , Substance P/metabolism , Trigeminal Nucleus, Spinal/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...